Ironwood Pharmaceuticals, Inc.

Forest Laboratories Holdings Limited

Ironwwod Pharmaceuticals, Inc.

Hong Zhao

Angelika Fretzen

Mahendra G Dedhiya

Steven Richard Witowski

Marco Kessler

Yun Mo

Alfredo Grossi

Robert Solinga

Vladimir Volchenok

Harvey Schneier

Bernard Joseph Lavins

Jeffrey Johnston

The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein, using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.

Treatments for gastrointestinal disorders

Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr ('linaclotide'; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.

Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration

The present invention relates to stable compositions comprising linaclotide, as well as to various methods and processes for the preparation and use of the compositions.

Formulations comprising linaclotide

Growing community of inventors

Lexington, MA, United States of America

Hong Zhao